Monte Rosa Therapeutics (GLUE) – Investment Analysts’ Recent Ratings Changes

A number of firms have modified their ratings and price targets on shares of Monte Rosa Therapeutics (NASDAQ: GLUE) recently:

• 1/14/2026 – Monte Rosa Therapeutics had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $37.00 price target on the stock, up previously from $27.50.
• 1/8/2026 – Monte Rosa Therapeutics had its price target raised by analysts at Wells Fargo & Company from $22.00 to $30.00. They now have an “overweight” rating on the stock.
• 1/8/2026 – Monte Rosa Therapeutics had its price target raised by analysts at Guggenheim from $16.00 to $34.00. They now have a “buy” rating on the stock.
• 1/7/2026 – Monte Rosa Therapeutics had its “buy” rating reaffirmed by analysts at Jefferies Financial Group Inc.. They now have a $31.00 price target on the stock.
• 1/7/2026 – Monte Rosa Therapeutics had its “buy” rating reaffirmed by analysts at TD Cowen.
• 1/7/2026 – Monte Rosa Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $37.00 price target on the stock.
• 1/6/2026 – Monte Rosa Therapeutics was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating.
• 12/29/2025 – Monte Rosa Therapeutics had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – Monte Rosa Therapeutics had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 12/17/2025 – Monte Rosa Therapeutics had its “buy” rating reaffirmed by analysts at Jefferies Financial Group Inc.. They now have a $22.00 price target on the stock.
• 12/15/2025 – Monte Rosa Therapeutics had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 12/9/2025 – Monte Rosa Therapeutics had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.

Insider Transactions at Monte Rosa Therapeutics

In other Monte Rosa Therapeutics news, CEO Markus Warmuth sold 5,466 shares of Monte Rosa Therapeutics stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $23.49, for a total value of $128,396.34. Following the completion of the sale, the chief executive officer owned 618,937 shares of the company’s stock, valued at approximately $14,538,830.13. The trade was a 0.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 6.50% of the company’s stock.

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.